Mesothelioma Publication - Hyaluronan

This is an abstract article concerning Mesothelioma and Hyaluronan published at PubMed by the NIH about.

Virchows Arch. 2005 Feb 25; [Epub ahead of print]

Hyaluronan synthase expression in pleural malignant mesotheliomas.

Kanomata N, Yokose T, Kamijo T, Yonou H, Hasebe T, Itano N, Kimata K, Ochiai A.

Pathology Division, National Cancer Center Research Institute East, 6-5-1 Kashiwanoha, 277-8577, Kashiwa, Chiba , Japan, aochiai@east.ncc.go.jp.

Hyaluronan (HA) is thought to play several important roles in tumor growth, tumorigenicity, and tumor dissemination and metastasis. Recently, three isoforms of hyaluronan synthase (HAS) have been cloned. Our objective was to determine which of the HAS isoforms were expressed in pleural malignant mesotheliomas, the most representative lesion of HA-producing tumors. We studied 10 cases of pleural malignant mesothelioma using novel antibodies of HAS. We compared HAS expression patterns of mesothelioma and pulmonary adenocarcinoma. Immunohistochemically, 9 of 10 (90%) cases of mesothelioma had extensive reaction to anti-HAS1 and anti-HAS2 antibodies, while HAS3 overexpression was present in 4 of 10 cases (40%). Of 20 cases of pulmonary adenocarcinoma, 5 overexpressed HAS1 (25%), 16 of 20 HAS2 (80%), and 4 of 20 HAS3 (20%). The expression level of HAS1 was significantly higher in mesotheliomas than in pulmonary adenocarcinoma (P=0.0036). Our data suggests that HAS1 might be a useful positive marker of malignant mesothelioma. However, a definitive conclusion should be based on further large-scale studies.

PMID: 15731923 [PubMed - as supplied by publisher]

For additional information about our mesothelioma lawyers and a complimentary consultation, speak to a Client Relations representative at Weitz & Luxenberg today! Please fill out this simple form, call toll free 1 (800) 476-6070 or e-mail us at Clientrelations@weitzlux.com.